Literature DB >> 16060697

Critical issues in the clinical management of complicated intra-abdominal infections.

Stijn Blot1, Jan J De Waele.   

Abstract

Intra-abdominal infections differ from other infections through the broad variety in causes and severity of the infection, the aetiology of which is often polymicrobial, the microbiological results that are difficult to interpret and the essential role of surgical intervention. From a clinical viewpoint, two major types of intra-abdominal infections can be distinguished: uncomplicated and complicated. In uncomplicated intra-abdominal infection, the infectious process only involves a single organ and no anatomical disruption is present. Generally, patients with such infections can be managed with surgical resection alone and no antimicrobial therapy besides perioperative prophylaxis is necessary. In complicated intra-abdominal infections, the infectious process proceeds beyond the organ that is the source of the infection, and causes either localised peritonitis, also referred to as abdominal abscess, or diffuse peritonitis, depending on the ability of the host to contain the process within a part of the abdominal cavity. In particular, complicated intra-abdominal infections are an important cause of morbidity and are more frequently associated with a poor prognosis. However, an early clinical diagnosis, followed by adequate source control to stop ongoing contamination and restore anatomical structures and physiological function, as well as prompt initiation of appropriate empirical therapy, can limit the associated mortality. The biggest challenge with complicated intra-abdominal infections is early recognition of the problem. Antimicrobial management is generally standardised and many regimens, either with monotherapy or combination therapy, have proven their efficacy. Routine coverage against enterococci is not recommended, but can be useful in particular clinical conditions such as the presence of septic shock in patients previously receiving prolonged treatment with cephalosporins, immunosuppressed patients at risk for bacteraemia, the presence of prosthetic heart valves and recurrent intra-abdominal infection accompanied by severe sepsis. In patients with prolonged hospital stay and antibacterial therapy, the likelihood of involvement of antibacterial-resistant pathogens must be taken into account. Antimicrobial coverage of Candida spp. is recommended when there is evidence of candidal involvement or in patients with specific risk factors for invasive candidiasis such as immunodeficiency and prolonged antibacterial exposure. In general, antimicrobial therapy should be continued for 5-7 days. If sepsis is still present after 1 week, a diagnostic work up should be performed, and if necessary a surgical reintervention should be considered.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16060697     DOI: 10.2165/00003495-200565120-00002

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  54 in total

1.  Duration of antifungal treatment and development of delayed complications in patients with candidaemia.

Authors:  A M L Oude Lashof; J P Donnelly; J F G M Meis; J W M van der Meer; B J Kullberg
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-01-25       Impact factor: 3.267

Review 2.  Appropriate empirical antibacterial therapy for nosocomial infections: getting it right the first time.

Authors:  Marin Kollef
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  Major trends in the microbial etiology of nosocomial infection.

Authors:  D R Schaberg; D H Culver; R P Gaynes
Journal:  Am J Med       Date:  1991-09-16       Impact factor: 4.965

Review 4.  Management of invasive candidiasis in critically ill patients.

Authors:  Stijn Blot; Koenraad Vandewoude
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 5.  Candida in pancreatic infection: a clinical experience.

Authors:  T Aloia; J Solomkin; A S Fink; M S Nussbaum; S Bjornson; R H Bell; L Sewak; D W McFadden
Journal:  Am Surg       Date:  1994-10       Impact factor: 0.688

6.  The impact of antimicrobial resistance on health and economic outcomes.

Authors:  Sara E Cosgrove; Yehuda Carmeli
Journal:  Clin Infect Dis       Date:  2003-05-16       Impact factor: 9.079

7.  Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock.

Authors:  R Phillip Dellinger; Jean M Carlet; Henry Masur; Herwig Gerlach; Thierry Calandra; Jonathan Cohen; Juan Gea-Banacloche; Didier Keh; John C Marshall; Margaret M Parker; Graham Ramsay; Janice L Zimmerman; Jean-Louis Vincent; M M Levy
Journal:  Intensive Care Med       Date:  2004-03-03       Impact factor: 17.440

8.  Implications of leukocytosis and fever at conclusion of antibiotic therapy for intra-abdominal sepsis.

Authors:  E S Lennard; E P Dellinger; M J Wertz; B H Minshew
Journal:  Ann Surg       Date:  1982-01       Impact factor: 12.969

9.  Factors affecting mortality in generalized postoperative peritonitis: multivariate analysis in 96 patients.

Authors:  Stefaan Mulier; Freddy Penninckx; Charles Verwaest; Ludo Filez; Raymond Aerts; Steffen Fieuws; Peter Lauwers
Journal:  World J Surg       Date:  2003-04       Impact factor: 3.352

10.  Relevance and risk factors of enterococcal bacteremia following liver transplantation.

Authors:  R Patel; A D Badley; J Larson-Keller; W S Harmsen; D M Ilstrup; R H Wiesner; J L Steers; R A Krom; D Portela; F R Cockerill; C V Paya
Journal:  Transplantation       Date:  1996-04-27       Impact factor: 4.939

View more
  35 in total

Review 1.  Antimicrobial Lessons From a Large Observational Cohort on Intra-abdominal Infections in Intensive Care Units.

Authors:  Dirk Vogelaers; Stijn Blot; Andries Van den Berge; Philippe Montravers
Journal:  Drugs       Date:  2021-05-26       Impact factor: 9.546

Review 2.  Candida peritonitis: an update on the latest research and treatments.

Authors:  Herman Anthony Carneiro; Anastasios Mavrakis; Eleftherios Mylonakis
Journal:  World J Surg       Date:  2011-12       Impact factor: 3.352

Review 3.  Management of peritonitis in the critically ill patient.

Authors:  Carlos A Ordoñez; Juan Carlos Puyana
Journal:  Surg Clin North Am       Date:  2006-12       Impact factor: 2.741

4.  Maximizing rates of empiric appropriate antibiotic therapy with minimized use of broad-spectrum agents: are surveillance cultures the key?

Authors:  S Blot; P Depuydt; D Vogelaers
Journal:  Intensive Care Med       Date:  2008-08-19       Impact factor: 17.440

5.  Canadian practice guidelines for surgical intra-abdominal infections.

Authors:  Anthony W Chow; Gerald A Evans; Avery B Nathens; Chad G Ball; Glen Hansen; Godfrey Km Harding; Andrew W Kirkpatrick; Karl Weiss; George G Zhanel
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

6.  Efficacy and safety of moxifloxacin in hospitalized patients with secondary peritonitis: pooled analysis of four randomized phase III trials.

Authors:  Jan J De Waele; Jose M Tellado; Günter Weiss; Jeffrey Alder; Frank Kruesmann; Pierre Arvis; Tajamul Hussain; Joseph S Solomkin
Journal:  Surg Infect (Larchmt)       Date:  2014-05-15       Impact factor: 2.150

7.  Profiling of Candida albicans gene expression during intra-abdominal candidiasis identifies biologic processes involved in pathogenesis.

Authors:  Shaoji Cheng; Cornelius J Clancy; Wenjie Xu; Frank Schneider; Binghua Hao; Aaron P Mitchell; M Hong Nguyen
Journal:  J Infect Dis       Date:  2013-09-04       Impact factor: 5.226

8.  A focus on intra-abdominal infections.

Authors:  Massimo Sartelli
Journal:  World J Emerg Surg       Date:  2010-03-19       Impact factor: 5.469

9.  Successful Kidney and Lung Transplantation From a Deceased Donor With Blunt Abdominal Trauma and Intestinal Perforation.

Authors:  Tim C van Smaalen; Christina Krikke; Jan Willem Haveman; L W Ernest van Heurn
Journal:  Transplant Direct       Date:  2015-12-23

10.  Treatment of perforated diverticulitis with generalized peritonitis: past, present, and future.

Authors:  Jefrey Vermeulen; Johan F Lange
Journal:  World J Surg       Date:  2010-03       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.